@rdecaluwe 💊500 miljoen is de cummulatieve meerkost berekend door @HLN_BE op meer dan 10 jaar, het cijfer 51 miljoen is de jaaruitgave. 💊 De gelijke veiligheid is al in 2014 bewezen 👇. https://t.co/iVxkfcl8et
"Health policies for the utilisation of ranibizumab [#Lucentis] instead of bevacizumab [#Avastin] as a routine intervention for neovascular AMD for reasons of systemic safety are not sustained by evidence." 👉 https://t.co/1Y7yTDtftH https://t.co/3DubyFfh
.@biosimilarz .@fgomollon it's is completely necessary to assess safety accurately (see Cochrane review at http://t.co/t1UzIz6o7R). 1/2
.@biosimilarz .@fgomollon it's is completely necessary to assess safety accurately (see Cochrane review at http://t.co/t1UzIz6o7R). 1/2
@reportime l'uso di #Lucentis vs #Avastin per ragioni di sicurezza non è giustificato dall'evidenza scientifica: http://t.co/1Gr63UIzGb
Un articolo interessante anche dal punto di vista sociale, dato il costo differente dei due farmaci : da seguire http://t.co/47uFDXo7sH
RT @CochraneLibrary: @DavidTovey discussing impact of Avastin review in #cochranehyd AGM. Read it here: http://t.co/VGtIF75hI4
@DavidTovey discussing impact of Avastin review in #cochranehyd AGM. Read it here: http://t.co/vTYRETwCgw
RT @CochraneLibrary: @DavidTovey discussing impact of Avastin review in #cochranehyd AGM. Read it here: http://t.co/VGtIF75hI4
@DavidTovey discussing impact of Avastin review in #cochranehyd AGM. Read it here: http://t.co/vTYRETwCgw
@DavidTovey discussing impact of Avastin review in #cochranehyd AGM. Read it here: http://t.co/vTYRETwCgw
@cochranecollab on aVEGFs in AMD. Dear @NICEcomms surely its time to review the TA? http://t.co/kOWtP4tFl4
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration [Cochrane] http://t.co/lC6neyEizw
Important new #CochraneEvidence on drugs for age-related macular degeneration from non-industry sponsored trials http://t.co/VWS6AhQjKh
Important new #CochraneEvidence on drugs for age-related macular degeneration from non-industry sponsored trials http://t.co/VWS6AhQjKh
Cheaper alternative to licensed drug for treating AMD has similar side-effects says new Cochrane Review http://t.co/r4mQ4vZ1t6 #IAPB1
#Metaanalisis #Cochrane Seguridad comparada de #Bevacizumab vs #Ranibizumab en DMAE http://t.co/dZmEGWCjUg @sefh_ @safh_info
#Metaanalisis #Cochrane Seguridad comparada de #Bevacizumab vs #Ranibizumab en DMAE http://t.co/dZmEGWCjUg @sefh_ @safh_info
Important new #CochraneEvidence on drugs for age-related macular degeneration from non-industry sponsored trials http://t.co/VWS6AhQjKh
Systemic safety of bevacizumab versus ranibizumab for neovascular agerelated macular degeneration #dmae #cochrane http://t.co/UFWk83nldA
Systemic safety of bevacizumab versus ranibizumab for neovascular agerelated macular degeneration #dmae #cochrane http://t.co/UFWk83nldA
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration [Cochrane] http://t.co/lC6neyEizw
Systemic safety of #bevacizumab vs #ranibizumab for neovascular agerelated macular degeneration: Cochrane Review http://t.co/IaceXaDlsY
Health policies for rani instead of beva for AMD for reasons of systemic safety are not sustained by evidence. Th http://t.co/FYPzMHLXQA
Systemic safety of #bevacizumab vs #ranibizumab for neovascular agerelated macular degeneration: Cochrane Review http://t.co/IaceXaDlsY
Systemic safety of bevacizumab versus ranibizumab for neovascular agerelated macular degeneration @CochraneLibrary http://t.co/UJcVgUr69G
Review concludes that Lucentis and considerably less expensive Avastin are equally safe in treatment of eye disease http://t.co/fAJ5NIGRga
Revisione #Cochrane: impiego intraoculare di #bevacizumab vs #ranibizumab, non ci sono differenze nella sicurezza: http://t.co/Ca7vTiNQq5
Revisione #Cochrane: impiego intraoculare di #bevacizumab vs #ranibizumab, non ci sono differenze nella sicurezza: http://t.co/Ca7vTiNQq5
Systemic safety of bevacizumab versus ranibizumab for neovascular related macular degeneration -The Cochrane Library http://t.co/WBK6QUEDMC
.@CochraneConsumr There is no evidence justifying the use of #Lucentis drug over cheaper #Avastin for safety reasons http://t.co/4VK7VwbF85
Gli effetti collaterali di Avastin e Lucentis, dice Cochrane, si equivalgono http://t.co/SolokZqKPC
Gli effetti collaterali di Avastin e Lucentis, dice Cochrane, si equivalgono http://t.co/SolokZqKPC
#CochraneEyes: Systemic (whole body) safety of bevacizumab versus ranibizumab for neovascular #AMD http://t.co/TPpV4GqEoT
.@CochraneConsumr There is no evidence justifying the use of #Lucentis drug over cheaper #Avastin for safety reasons http://t.co/4VK7VwbF85
Systemic (whole body) safety of bevacizumab versus ranibizumab for neovascular age-related… http://t.co/MzfjuCCPiP
.@CochraneConsumr There is no evidence justifying the use of #Lucentis drug over cheaper #Avastin for safety reasons http://t.co/4VK7VwbF85
.@CochraneConsumr There is no evidence justifying the use of #Lucentis drug over cheaper #Avastin for safety reasons http://t.co/4VK7VwbF85
.@CochraneConsumr There is no evidence justifying the use of #Lucentis drug over cheaper #Avastin for safety reasons http://t.co/4VK7VwbF85
.@CochraneConsumr There is no evidence justifying the use of #Lucentis drug over cheaper #Avastin for safety reasons http://t.co/4VK7VwbF85
@CochraneConsumr:Use of #Lucentis over #Avastin for safety reasons is not justified by evidence. http://t.co/1Gr63UIzGb